David Zaccardelli net worth and biography

David Zaccardelli Biography and Net Worth

CEO of Verona Pharma

From December 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Dr Zaccardelli served as President and CEO of Dova Pharmaceuticals, a US company developing therapeutics for rare diseases. Previously, he was Acting CEO of Cempra, from December 2016 until the company’s merger with Melinta Therapeutics in November 2017. From 2004 until 2016, Dr Zaccardelli served in several senior management roles at United Therapeutics Corporation, including Chief Operating Officer, Chief Manufacturing Officer and Executive Vice President, Pharmaceutical Development and Operations. Prior to United Therapeutics, he founded and led a start-up company focused on contract research positions and held a variety of clinical research positions at Burroughs Wellcome & Co, Glaxo Wellcome, and Bausch & Lomb Pharmaceutical. Dr Zaccardelli received a Pharm.D. from the University of Michigan.

What is David Zaccardelli's net worth?: The estimated net worth of David Zaccardelli is at least $831.55 million as of December 6th, 2024. Dr. Zaccardelli owns 14,204,752 shares of Verona Pharma stock worth more than $831,546,182 as of April 1st. This net worth approximation does not reflect any other investments that Dr. Zaccardelli may own. Additionally, Dr. Zaccardelli receives an annual salary of $1,270,000.00 as CEO at Verona Pharma. Learn More about David Zaccardelli's net worth.
How old is David Zaccardelli?: Dr. Zaccardelli is currently 60 years old. There are 4 older executives and no younger executives at Verona Pharma. Learn More on David Zaccardelli's age.
What is David Zaccardelli's salary?: As the CEO of Verona Pharma plc, Dr. Zaccardelli earns $1,270,000.00 per year. Learn More on David Zaccardelli's salary.
How do I contact David Zaccardelli?: The corporate mailing address for Dr. Zaccardelli and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at verona@argotpartners.com. Learn More on David Zaccardelli's contact information.
Has David Zaccardelli been buying or selling shares of Verona Pharma?: David Zaccardelli has not been actively trading shares of Verona Pharma within the last three months. Most recently, David Zaccardelli sold 162,800 shares of the business's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $5.01, for a transaction totalling $815,628.00. Following the completion of the sale, the chief executive officer now directly owns 14,204,752 shares of the company's stock, valued at $71,165,807.52. Learn More on David Zaccardelli's trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 1 times. They purchased a total of 39,360 shares worth more than $188,928.00. In the last year, insiders at the sold shares 26 times. They sold a total of 2,209,944 shares worth more than $10,481,733.68. The most recent insider tranaction occured on March, 12th when insider Kathleen A Rickard sold 79,264 shares worth more than $661,854.40. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 3/12/2025.

David Zaccardelli Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2024	Sell	162,800	$5.01	$815,628.00	14,204,752
12/4/2024	Sell	67,608	$5.00	$338,040.00	15,007,816
12/2/2024	Sell	3,200	$5.00	$16,000.00	15,075,424
11/29/2024	Sell	98,888	$5.01	$495,428.88	15,078,624
11/27/2024	Sell	23,240	$5.00	$116,200.00	15,177,512
11/11/2024	Sell	2,400	$5.00	$12,000.00	15,202,352
11/4/2024	Sell	94,144	$4.39	$413,292.16	15,204,752
11/1/2024	Sell	46,888	$4.38	$205,369.44	15,298,896
10/25/2024	Sell	4,800	$4.38	$21,024.00	14,591,736
10/23/2024	Sell	16	$4.38	$70.08	14,736,536
10/21/2024	Sell	110,456	$4.38	$483,797.28	14,894,464
10/18/2024	Sell	245,784	$4.38	$1,076,533.92	15,004,920
8/7/2023	Sell	8,616	$2.47	$21,281.52	16,431,800
8/4/2023	Sell	150,000	$2.50	$375,000.00	16,440,416
8/2/2023	Sell	73,704	$2.59	$190,893.36	16,707,688
5/1/2023	Sell	455,536	$2.58	$1,175,282.88	16,887,336
2/1/2023	Sell	432,928	$2.56	$1,108,295.68	17,342,872
12/20/2022	Sell	600,000	$2.12	$1,272,000.00	17,775,800
8/9/2022	Sell	600,000	$1.75	$1,050,000.00	15,263,560
8/1/2022	Sell	32,904	$0.70	$23,032.80	15,863,560
5/3/2022	Sell	32,904	$0.50	$16,452.00	16,351,328
2/3/2022	Sell	52,056	$0.73	$38,000.88
11/2/2021	Sell	52,056	$0.64	$33,315.84
8/3/2021	Sell	16,000	$0.76	$12,160.00
3/1/2021	Sell	43,392	$1.14	$49,466.88

See Full Table

David Zaccardelli Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $58.54

$58.40

$63.75

50 Day Range

MA: $62.53

$53.09

$69.63

2 Week Range

Now: $58.54

$11.39

$70.40

Volume

2,238,774 shs

Average Volume

1,159,978 shs

Market Capitalization

$4.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

David Zaccardelli Biography and Net Worth

What is David Zaccardelli's net worth?

How old is David Zaccardelli?

What is David Zaccardelli's salary?

How do I contact David Zaccardelli?

Has David Zaccardelli been buying or selling shares of Verona Pharma?

Who are Verona Pharma's active insiders?

Are insiders buying or selling shares of Verona Pharma?